Table 3.
Clinicopathological variables for cats included in the retrospective cohort study grouped according to renal status and development of total hypercalcemia
| Variable (Reference Interval) | H‐NCa (n = 166) | H‐HCa (n = 10) | CKD‐NCa (n = 131) | CKD‐HCa (n = 60) | ||||
|---|---|---|---|---|---|---|---|---|
| Median [25th, 75th Percentile] | n | Median [25th, 75th Percentile] | n | Median [25th, 75th Percentile] | n | Median [25th, 75th Percentile] | n | |
| Age (years) | 12.0 [10.4, 14.0]a | 161 | 13.9 [10.6, 14.7] | 10 | 14.6 [12.0, 16.1]b | 117 | 13.8 [12.0, 15.7]b | 56 |
| Weight (kg) | 4.43 [3.53, 5.29]a | 161 | 4.29 [3.71, 5.76] | 10 | 3.94 [3.39, 4.71]b | 128 | 4.16 [3.21, 4.94] | 60 |
| % Male | 49 | 166 | 30 | 10 | 52 | 131 | 43 | 60 |
| % Longhair | 18 | 166 | 20 | 10 | 15 | 131 | 12 | 60 |
| Albumin (2.5–4.5 g/dL) | 3.2 [3.1, 3.4] | 166 | 3.4 [3.2, 3.5] | 10 | 3.1 [3.0, 3.3] | 131 | 3.1 [2.9, 3.4] | 60 |
| Calcidiol (65–170 nmol/L) | – | 0 | – | 0 | 140.5 [128.3, 171.5] | 14 | 144.0 [110.0, 211.0] | 11 |
| Calcitriol (90–342 pmol/L) | – | 0 | – | 0 | 418.0 [366.0, 447.0] | 15 | 320.0 [116.0, 475.0] | 11 |
| Chloride (100–124 mEq/L) | 119 [117, 120] | 166 | 118 [117, 120] | 10 | 118 [116, 121] | 131 | 118 [116, 120] | 60 |
| Creatinine (0.23–2.00 mg/dL) | 1.47 [1.34, 1.70]a | 166 | 1.59 [1.34, 2.04]a | 10 | 2.37 [2.13, 2.68]b | 131 | 2.42 [2.19, 2.90]b | 60 |
| FGF‐23 (56–700 pg/mL) | 164 [108, 243]a | 57 | 261 [221, 604] | 6 | 491 [283, 1035]b | 62 | 518 [342, 1701]b | 29 |
| iCa (4.76–5.48 mg/dL) | 5.08 [5.00, 5.24] | 35 | 5.16 [–] | 3 | 5.16 [5.02, 5.32]a | 37 | 5.34 [5.20, 5.44]b | 24 |
| PCV (30–45%) | 38 [34, 40]a | 162 | 39 [36, 42] | 10 | 35 [31, 38]b | 129 | 35 [30, 39] | 59 |
| Venous pH (7.21–7.44) | 7.35 [7.32, 7.38] | 35 | 7.35 [–] | 3 | 7.36 [7.31, 7.39] | 33 | 7.35 [7.31, 7.37] | 22 |
| Phosphate (2.79–6.81 mg/dL) | 3.84 [3.35, 4.37] | 166 | 3.53 [3.18, 4.46] | 10 | 4.03 [3.50, 4.84] | 131 | 4.12 [3.43, 4.95] | 60 |
| Potassium (3.5–5.5 mEq/L) | 3.9 [3.7, 4.3] | 164 | 4.0 [3.8, 4.2] | 10 | 4.0 [3.7, 4.3] | 130 | 4.1 [3.8, 4.3] | 60 |
| PTH (2.6–17.6 pg/mL) | 7.0 [2.6, 12.0]a | 31 | 4.6 [2.6, 7.1]a | 4 | 15.0 [8.7, 27.7]b | 62 | 7.9 [2.6, 22.0]a | 30 |
| SBP (<160 mmHg) | 136 [122, 152] | 165 | 134 [121, 159] | 10 | 142 [126,158] | 131 | 138 [123, 156] | 60 |
| Sodium (145–157 mEq/L) | 152.3 [150.9, 153.8] | 165 | 151.9 [150.5, 153.9] | 10 | 152.5 [150.8, 154.6] | 130 | 152.9 [150.0, 154.6] | 60 |
| tCa (8.2–11.8 mg/dL) | 9.8 [9.5, 10.2]a | 166 | 10.6 [9.7, 11.3]b | 10 | 10.1 [9.7, 10.4]b,c | 131 | 10.4 [10.0, 11.0]b,d | 60 |
| Total protein (6.0–8.0 g/dL) | 7.6 [7.3, 8.1] | 166 | 7.5 [7.1, 7.8] | 10 | 7.8 [7.4, 8.1] | 131 | 7.7 [7.4, 8.1] | 60 |
| Urea (7.0–27.7 mg/dL) | 29.1 [24.9, 32.8]a | 166 | 27.8 [24.3, 33.8]a | 10 | 47.3 [39.9, 55.7]b | 131 | 45.4 [37.7, 55.6]b | 60 |
| USG (≥1.035) | 1.044 [1.031, 1.056]a | 108 | 1.060 [1.041, 1.070]a | 5 | 1.020 [1.016, 1.022]b | 101 | 1.020 [1.016, 1.024]b | 44 |
| Follow‐up (days) | 732 [516, 1023]a | 166 | 386 [166, 542]b | 10 | 679 [490, 1022]a | 131 | 175 [63, 403]b | 60 |
H‐NCa, apparently healthy‐normocalcemic; H‐HCa, apparently healthy‐developed hypercalcemia; CKD‐NCa, CKD‐normocalcemic; CKD‐HCa, CKD‐developed hypercalcemia; n, number of cats; FGF‐23, fibroblast growth factor 23; PTH, parathyroid hormone; SBP, systolic blood pressure; USG, urine specific gravity; P, significance.
Rows bearing a different superscript letter are significantly different from one another.